Literature DB >> 29150742

Associations Between Nucleus Size, and Immunohistochemical Galectin-3, Cytokeratine-19 and Hbme-1 Markers in Thyroid Papillary Carcinoma: A Morphometric Analyze.

Hatice Toy1, Ozlem Etli2, Zeliha Esin Celik3, Arsenal Sezgin Alikanoglu4.   

Abstract

This study aimed to evaluate the morphometric measurements in cases with papillary thyroid carcinoma, and determine a cut-off value to support diagnosis. Fifty cases with a diagnosis of papillary thyroid carcinoma (PTC) were included in the study with their Galectine-3, CK-19 and HBME-1 immunohistochemical staining results. Demographic and clinical data gathered from pathology reports, which included demographic information such as patients' sex, age, macroscopic tumor size, number of tumor focuses; prognostic parameters such as lenfovascular invasion, perineural invasion, thyroid capsule invasion; and results of immunohistochemical CK- 19, Galectin-3 and HBME-1 staining. Longest nuclear diameters of 150 tumor cells and 150 normal thyrocytes of each case were manually measured in an image analysis software, and mean longest nuclear diameters (MLND-TC and MLND-NC), and also tumor cell/normal cell longest nuclear diameter ratio (TC/NC-LNDR) were calculated. MLND-TC was higher than MLND-NC. The cases with higher MLND-TC had increased risk of capsule invasion in case of a negative staining with Galectine-3, HBME-1, or CK-19. When TC/NC-LNDR was high, number of tumor focus tended to be multiple and lymphovascular invasion risk was also increased. Subtypes of PTC were not differed regarding staining patterns. And finally, increased TC/NC-LNDR was associated with increased risk of having poor prognostic factors. The results of this study suggest that MLND-NC, MLND-TC, and TC/NCLNDR are valuable and easy-to-use measures, which can assist routine histology practice.

Entities:  

Keywords:  Morphometric analyze; Nucleus diameter; Papillary thyroid carcinoma

Mesh:

Substances:

Year:  2017        PMID: 29150742     DOI: 10.1007/s12253-017-0337-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  17 in total

Review 1.  Nuclear structure in cancer cells.

Authors:  Daniele Zink; Andrew H Fischer; Jeffrey A Nickerson
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

Review 2.  Quantitative analysis of nuclear size for objective malignancy grading: a review with emphasis on new, unbiased stereologic methods.

Authors:  F B Sørensen
Journal:  Lab Invest       Date:  1992-01       Impact factor: 5.662

3.  Immunohistochemical diagnosis of papillary thyroid carcinoma.

Authors:  C C Cheung; S Ezzat; J L Freeman; I B Rosen; S L Asa
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

4.  Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.

Authors:  P S de Matos; A P Ferreira; F de Oliveira Facuri; L V M Assumpção; K Metze; L S Ward
Journal:  Histopathology       Date:  2005-10       Impact factor: 5.087

5.  Comparison of morphonuclear features in normal, benign and neoplastic thyroid tissue by digital cell image analysis.

Authors:  I Salmon; R Kiss; B Franc; P Gasperin; R Heimann; J L Pasteels; A Verhest
Journal:  Anal Quant Cytol Histol       Date:  1992-02       Impact factor: 0.302

6.  Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.

Authors:  K T Mai; R Bokhary; H M Yazdi; J Thomas; A S Commons
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

7.  Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.

Authors:  A Coli; Giulio Bigotti; F Zucchetti; F Negro; G Massi
Journal:  Histopathology       Date:  2002-01       Impact factor: 5.087

8.  Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma.

Authors:  E Saggiorato; S Cappia; P De Giuli; A Mussa; G Pancani; P Caraci; A Angeli; F Orlandi
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

9.  The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.

Authors:  Katie B Weber; Kenneth R Shroyer; David E Heinz; Samia Nawaz; M Sherif Said; Bryan R Haugen
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

10.  Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.

Authors:  Michelle Wallander; Lester J Layfield; Elke Jarboe; Lyska Emerson; Ting Liu; Harshwardhan Thaker; Joseph Holden; Sheryl Tripp
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-05
View more
  3 in total

1.  The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.

Authors:  Xueyang Yang; Yifang Hu; He Shi; Chengzhou Zhang; Zhixiao Wang; Xiaoyun Liu; Huanhuan Chen; Lijuan Zhang; Dai Cui
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-06-27       Impact factor: 2.503

2.  Diagnostic and prognostic value of Stanniocalcin 1 expression in papillary thyroid cancer.

Authors:  Sevinç Sengun; Hakan Korkmaz; Metin Ciris; Ramazan Oguz Yüceer; Serife Mehtap Boyluboy; Mehmet Kiran
Journal:  Endocrine       Date:  2022-07-04       Impact factor: 3.925

3.  Lectin affinity chromatography and quantitative proteomic analysis reveal that galectin-3 is associated with metastasis in nasopharyngeal carcinoma.

Authors:  Sathid Aimjongjun; Onrapak Reamtong; Tavan Janvilisri
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.